Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach